IBOGAINE Act

This bill defines ibogaine in federal drug law and creates a pilot program, running through September 30, 2029, that gives drug makers a voucher for faster FDA review when they win approval of a drug for a national health priority. It would let doctors register with the Attorney General to give certain Schedule I experimental drugs to eligible patients under the federal right-to-try law. It would require the Attorney General to revise drug production quotas after certain events, to begin steps within 60 days to decide whether to move ibogaine from Schedule I to Schedule II, and to start rescheduling reviews for Schedule I mental health drugs that complete phase 3 trials. It also allows federal health agencies to partner with states and tribes on psychedelic drug research and requires the Department of Veterans Affairs to name an official for emerging therapies, report on that work, and plan staff training.

Full text and official record on Congress.gov

Sponsors

• Morgan Luttrell Republican sponsor
• 5 cosponsors